BNTX vs. MRNA

Last updated Apr 2, 2026

Compare and contrast key facts about BioNTech SE (BNTX) and Moderna, Inc. (MRNA).

Performance

BNTX vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioNTech SE (BNTX) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

BNTX vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BNTX BioNTech SE	-6.07%	-16.45%	7.97%	-29.74%	-40.40%	216.24%	140.61%	137.92%
MRNA Moderna, Inc.	69.65%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	38.14%

Fundamentals

Market Cap BNTX : $21.92B MRNA : $19.61B
EPS BNTX : -$4.68 MRNA : -$7.24
PS Ratio BNTX : 7.56 MRNA : 10.04
PB Ratio BNTX : 1.14 MRNA : 2.27
Total Revenue (TTM) BNTX : $2.86B MRNA : $1.94B
Gross Profit (TTM) BNTX : $2.22B MRNA : $274.00M
EBITDA (TTM) BNTX : -$635.06M MRNA : -$2.61B

Returns By Period

In the year-to-date period, BNTX achieves a -6.07% return, which is significantly lower than MRNA's 69.65% return.

BNTX

• 1D: 0.61%
• 1M: -16.80%
• YTD: -6.07%
• 6M: -12.51%
• 1Y: -0.96%
• 3Y*: -10.46%
• 5Y*: -4.29%
• 10Y*: —

MRNA

• 1D: -1.52%
• 1M: -5.33%
• YTD: 69.65%
• 6M: 81.27%
• 1Y: 84.20%
• 3Y*: -31.19%
• 5Y*: -17.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BNTX vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNTX

BNTX Risk / Return Rank: 38
BNTX Sharpe Ratio Rank: 39
BNTX Sortino Ratio Rank: 37
BNTX Omega Ratio Rank: 38
BNTX Calmar Ratio Rank: 39
BNTX Martin Ratio Rank: 38

MRNA

MRNA Risk / Return Rank: 77
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 78
MRNA Omega Ratio Rank: 73
MRNA Calmar Ratio Rank: 78
MRNA Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BNTX vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioNTech SE (BNTX) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BNTX	MRNA	Difference
Sharpe ratio Return per unit of total volatility	-0.02	1.28	-1.30
Sortino ratio Return per unit of downside risk	0.33	2.02	-1.69
Omega ratio Gain probability vs. loss probability	1.05	1.24	-0.19
Calmar ratio Return relative to maximum drawdown	-0.06	2.15	-2.21
Martin ratio Return relative to average drawdown	-0.12	4.44	-4.56
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BNTX vs. MRNA - Sharpe Ratio Comparison

The current BNTX Sharpe Ratio is -0.02, which is lower than the MRNA Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of BNTX and MRNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BNTX	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.02	1.28	-1.30
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.08	-0.27	+0.19
Sharpe Ratio (All Time) Calculated using the full available price history	0.43	0.20	+0.23

Correlation

The correlation between BNTX and MRNA is 0.56, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

BNTX vs. MRNA - Dividend Comparison

Neither BNTX nor MRNA has paid dividends to shareholders.

	TTM	2025	2024	2023	2022
BNTX BioNTech SE	0.00%	0.00%	0.00%	0.00%	2.43%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

BNTX vs. MRNA - Drawdown Comparison

The maximum BNTX drawdown since its inception was -82.08%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for BNTX and MRNA.

Drawdown Indicators

	BNTX	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-82.08%	-95.38%	+13.30%
Max Drawdown (1Y) Largest decline over 1 year	-30.40%	-35.51%	+5.11%
Max Drawdown (5Y) Largest decline over 5 years	-82.08%	-95.38%	+13.30%
Current Drawdown Current decline from peak	-79.55%	-89.67%	+10.12%
Average Drawdown Average peak-to-trough decline	-55.54%	-55.87%	+0.33%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.12%	17.21%	-2.09%

Volatility

BNTX vs. MRNA - Volatility Comparison

BioNTech SE (BNTX) has a higher volatility of 23.89% compared to Moderna, Inc. (MRNA) at 22.27%. This indicates that BNTX's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BNTX	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.89%	22.27%	+1.62%
Volatility (6M) Calculated over the trailing 6-month period	33.34%	50.95%	-17.61%
Volatility (1Y) Calculated over the trailing 1-year period	50.27%	66.40%	-16.13%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.09%	66.59%	-9.50%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.08%	72.29%	+4.79%

Financials